Clinical trials: Prostate Cancers
Prostate Cancer
Evaluate Recovery of Testosterone for Patients Using Eligard
The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.
- Trial name
- Eligard (NCT01136226)
- Testing
- Eligard (TM)
- Volunteers
- 42 people
- Sponsor
- Chesapeake Urology Research Associates
Melanoma, Prostate Cancer
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study
- Conditions
- Melanoma, Prostate Cancer, Renal Cancer
- Trial name
- NCT01650350
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Brown University
Prostate Cancer
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
Background: GE-148 (18F) is a new drug that is designed to attach to prostate cancer cells. Researchers are interested in combining the drug with a small amount of radioactive material to allow prostate cancer lesions to appear…
- Trial name
- NCT01176513
- Testing
- GE-148 (18F)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GE Healthcare
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00536991
- Testing
- Calcitriol, Ketoconazole, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer, Prostatic Neoplasms
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
This study evaluates if itraconazole causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer
- Trial name
- NCT01450683
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Prostate Cancer
Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)
Solid tumors, including prostate cancer, commonly exhibit tumor-associated neovascularity (growth of new blood vessels to feed the tumor) with increased microvessel density.
- Trial name
- NCT00635167
- Testing
- Contrast Enhanced-Transrectal Ultrasound
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hormone Refractory Prostate Cancer
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).
- Trial name
- NCT00629525
- Testing
- RAD001
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Daniel George, MD
Prostate Cancer
Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
Men treated with neoadjuvant luteinizing hormone-releasing hormone (LHRH)-agonists such as leuprolide and goserelin for prostate cancer will become hypogonadal due to hormonal suppression and demonstrate increased bone turnover…
- Trial name
- NCT00859027
- Testing
- risedronate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UConn Health
Prostate Neoplasms
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Following pretreatment evaluation, patients receive PS-341 by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest period. This schedule consists of one treatment cycle.
- Trial name
- NCT00425503
- Testing
- PS-341 (bortezomib)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Baylor College of Medicine
Prostate Cancer
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in…
- Trial name
- PRESERVE (NCT04972097)
- Testing
- Irreversible Electroporation
- Where
- 17 sites in United States
- Volunteers
- 121 people
- Sponsor
- Angiodynamics, Inc.
High Cholesterol, High Blood Pressure
Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey
The purpose of this study is to survey a sample of adults who have recently made a decision about treatment of high cholesterol or high blood pressure or a decision about screening for colorectal cancer, breast cancer, or…
- Conditions
- High Cholesterol, High Blood Pressure, Colorectal Cancer, Breast Cancer
- Trial name
- NCT04317690
- Where
- United States
- Volunteers
- 539 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
The purpose of this research study is to determine if an investigational drug called Exisulind will extend the "off-treatment" period of patients receiving Intermittent Androgen Suppression (ADT).
- Trial name
- NCT00283803
- Testing
- Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer
This trial is designed as a randomized two-arm (LDE225 vs. observation groups) open-label prospective clinical trial in men with localized high-risk prostate cancer undergoing radical prostatectomy.
- Trial name
- LDE225 (NCT02111187)
- Testing
- LDE225
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05256381
- Testing
- Nanrilkefusp Alfa, Pembrolizumab
- Where
- 54 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- SOTIO Biotech AG
Breast Cancer, Colorectal Cancer
Validation of a Screening Tool in Geriatric Oncology
RATIONALE: A screening questionnaire may help doctors plan better treatment for older patients with cancer. PURPOSE: This clinical trial is studying a questionnaire in screening older patients with cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- ONCODAGE (NCT00963911)
- Testing
- Geriatric screening tests, Multidimensional geriatric assessment
- Where
- France
- Volunteers
- 1,674 people
- Sponsor
- Institut Bergonié
Prostate Cancer
VMAT for Dominant Intraprostatic Lesion
The aim of this study was to determine the efficacy and safety of the implementation of a program of " image-guided focal Intensification dose to intraprostatic dominant lesion " in men with localized prostate cancer (PCa) of…
- Trial name
- CaP-VMAT-DIL (NCT03030625)
- Testing
- IGRT/VMAT focal therapy boost to DIL
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Prostate Cancer
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
The purpose of this study is to describe the rate of 3-year progression free survival in men with recurrent PSA-only disease after prostatectomy, who receive combined apalutamide (ARN-509) and standard ADT with salvage radiation…
- Trial name
- NCT03311555
- Testing
- Apalutamide, Androgen deprivation, Salvage radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Andrew J. Armstrong, MD
Prostate Cancer
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
The purpose of this study is to assess two treatment strategies (leuprorelin treatment and active surveillance without androgen deprivation) for indolent prostate cancer and to compare their therapeutic benefit for management of…
- Trial name
- NCT02085252
- Testing
- Leuprorelin, Bicalutamide
- Where
- 2 sites in France
- Volunteers
- 116 people
- Sponsor
- Takeda
Castration-resistant Prostate Cancer, Stage IV Prostate Cancer
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
This randomized phase II trial studies the best way to give abiraterone acetate in treating patients with castration-resistant prostate cancer.
- Trial name
- NCT01543776
- Testing
- abiraterone acetate
- Where
- 6 sites in United States, Singapore
- Volunteers
- 72 people
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.